Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 13/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30859099 | 0.87 | TYMP (0.71) | TYMPTAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL19841777 | 0.87 | TYMP (0.71) | TYMPTAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL30603353 | 0.87 | TYMP (0.52) | TYMP | |
| SCHEMBL19841776 | 0.86 | TYMP (0.59) | TYMPTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL29531573 | 0.83 | TYMP (0.57) | TYMPTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL22408781 | 0.83 | TYMP (0.57) | TYMPTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL19362154 | 0.83 | TYMP (0.57) | TYMPTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL16326506 | 0.83 | TYMP (0.43) | TYMPTAS1R3TAS1R1NT5EHINT1 | |
| SCHEMBL30540710 | 0.83 | TYMP (0.49) | TYMPTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL9706215 | 0.83 | TAS1R3 (0.60) | TYMPTAS1R3TAS1R1NT5EIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509485-B2 | Method for producing nucleic acid oligomer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20250145655-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-4488282-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | Sumitomo Chemical Company, Limited (JP) | 2025-01-08 | — | — | EP | disclosed |
| WO-2022064908-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | 住友化学株式会社 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145655-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLRMT, RNGTT, POLM | TYMP 458/4885TAS1R3 1510/4885TAS1R1 2217/4885 |
| US-12509485-B2 | Method for producing nucleic acid oligomer | RNGTT, POLM, NSUN2 | TYMP 365/4885TAS1R3 2210/4885TAS1R1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.